We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Akashi Therapeutics on Wednesday announced that it received approval from the FDA to restart clinical studies of the experimental Duchenne muscular dystrophy (DMD) treatment HT-100.